About

iSERA Lifesciences Ltd operates in Computers - Software & Consulting within the Information Technology sector.

Face value: ₹10

Market cap

₹121 Cr

P/E

—

P/B

14.7×

Dividend yield

0%

ROE

3.2%

ROCE

6%

Debt / equity

0

OPM

19.9%

EPS (TTM)

₹-0.3

Book value

₹9.8

52-week high

₹151.1

52-week low

₹3.1

₹143.9+4,497.4%1Y

Volatility (1y)

16.3%

Annualised, daily returns

RSI (14)

50

Neither overbought nor oversold

Rel. strength (1y)

4,578.5%

Ahead of the market

Quick read

rule-based

Pros

+Almost debt-free (debt/equity 0)
+Outperformed the universe by 4578.5% over 1 year

Cons

−Low return on equity of 3.2% (3-yr avg)
−Trading at 14.7× book value
−Promoter holding fell 34.1 pts over the last year

Research score

Structured signal from quality, growth, valuation and momentum.

46/100

Business quality: 38
Valuation: 0
Momentum

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Persistent Systems LimitedPERSISTENTPERSISTENT	₹84,691 Cr	₹84,691 Cr	₹15,718 Cr	₹2,881 Cr	19%	₹1,923 Cr	12.7%	34.2%	26.3%	48
Coforge LimitedCOFORGECOFORGE	₹80,837 Cr	₹81,237 Cr	₹18,152 Cr	₹3,397 Cr	17.9%	₹1,717 Cr	10.6%	22.2%	19.7%	88
Mphasis LimitedMPHASISMPHASIS	₹42,956 Cr	₹44,749 Cr	₹16,531 Cr	₹3,071 Cr	18.8%	₹1,910 Cr	11.7%	24.7%	18.3%	58
Hexaware Technologies LimitedHEXTHEXT	₹29,966 Cr	₹29,966 Cr	₹14,420 Cr	₹2,155 Cr	14.2%	₹1,344 Cr	10.2%	—	—	—
Tata Elxsi LimitedTATAELXSITATAELXSI	₹19,268 Cr	₹19,268 Cr	₹3,886 Cr	₹876 Cr	22.5%	₹655 Cr	16.7%	29.9%	21.3%	-54
Fractal Analytics LimitedFRACTALFRACTAL	₹12,510 Cr	₹12,796 Cr	₹3,300 Cr	₹508 Cr	15.4%	₹292 Cr	8.7%	15.3%	11.8%	61
Rategain Travel Technologies LimitedRATEGAINRATEGAIN	₹9,953 Cr	₹10,875 Cr	₹2,336 Cr	₹459 Cr	18.5%	₹242 Cr	10.7%	13.8%	10.5%	36
Zensar Technologies LimitedZENSARTECHZENSARTECH	₹9,881 Cr	₹9,881 Cr	₹5,811 Cr	₹926 Cr	16.1%	₹776 Cr	13.6%	23%	17.6%	31
ASM Technologies LtdASMTECASMTEC	₹9,641 Cr	₹9,754 Cr	₹529 Cr	₹101 Cr	19.1%	₹26 Cr	11.5%	33.3%	25.7%	202
Intellect Design Arena LimitedINTELLECTINTELLECT	₹8,566 Cr	₹8,566 Cr	₹3,182 Cr	₹603 Cr	19.1%	₹351 Cr	11.3%	15.6%	11.6%	46
Birlasoft LimitedBSOFTBSOFT	₹7,542 Cr	₹7,551 Cr	₹5,404 Cr	₹930 Cr	16.3%	₹573 Cr	9.8%	21.2%	13.7%	63
Sonata Software LimitedSONATSOFTWSONATSOFTW	₹7,124 Cr	₹7,692 Cr	₹11,015 Cr	₹752 Cr	6.9%	₹463 Cr	4.3%	32.4%	25.7%	-19

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	25	21	29	12	0	0	0	0	0	1
	25	21	28	12	0	0	0	0	0	1
	1	0	0	0	-0	0	-0	-0	-0	0
OPM %	2%	2.3%	1.5%	2.8%	—	—	—	—	—	19.9%
Depreciation	0	0	—	—	0	0	0	0	0	0
Interest	—	0	0	0	0	0	0	0	0	0
	—	—	—	—	0	0	0	0	0	0
Profit before tax	0	0	0	0	-0	0	-0	-0	0	0
Tax	0	0	0	—	0	0	0	0	0	0
Tax %	41.7%	75%	0%	—	0%	—	0%	0%	0%	23.5%
	-13	0	0	-0	-0	0	-0	-0	0	0
PAT margin %	-49.3%	0.1%	0.1%	-0.2%	—	—	—	—	—	19.1%
EPS (₹)	-11.8	0	—	—	-0.2	0	-3.7	-3.3	4.3	0.7
EPS adjusted (₹)	—	—	—	—	-0.2	0	-3.7	-3.3	4.4	0.3
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	11	0	0	0	0	8
Reserves	-11	-0	-0	-1	-0	-0
Minority interest	—	0	—	—	—	—
	2	0	0	0	2	0
	3	0	0	0	0	2
Total equity & liabilities	5	0	0	0	2	11
	0	0	0	0	0	0
CWIP	0	0	0	—	—	0
Investments	0	0	0	0	0	0
	4	—	0	0	2	11
Total assets	5	0	0	0	2	11

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	4	12	-0	-0	-1	-5
	4	0	0	0	0	0
	5	-12	0	0	1	8
Net cash flow	13	0	0	-0	0	3
Free cash flow	4	12	-0	-0	-1	-5
CFO / Operating profit %	—	—	—	—	—	—

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2018	Mar 2019	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	—	—	—	—	—	—
EBITDA margin %	1.5%	2.8%	—	—	—	—	—	19.9%
EBIT margin %	1.5%	2.8%	—	—	—	—	—	19.9%
PAT margin %	0.1%	-0.2%	—	—	—	—	—	19.1%
Working capital
Receivable days	—	—	—	—	—	—	—	322
Inventory days	—	—	—	—	—	—	—	0
Payable days	—	—	—	—	—	—	—	167
NWC days	—	—	—	—	—	—	—	155
Leverage
Current ratio	—	—	0	0	1.25	0.56	31	6.65
Debt to EBITDA	—	—	—	—	—	—	—	0
Debt to equity	—	—	-16.83	-0	-1.08	-0.82	-16.1	0
Interest coverage	1.6	1.4	-10.5	—	—	—	—	—
Asset turnover	—	—	0	—	0	0	0	0.13
Return ratios
Return on assets %	—	—	-5.1%	—	-220%	-200%	9%	2.5%
Return on capital employed %	—	—	-10.8%	0%	-1,100%	666.7%	9.3%	6%
Return on equity %	—	—	191.7%	-0%	91.7%	45.5%	-140%	3.2%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	100%	26.35%	26.35%	26.35%	26.35%	26.35%	26.35%	92.76%	92.76%	3.57%	58.63%	58.63%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	0%	73.65%	73.65%	73.65%	73.65%	73.65%	73.65%	7.24%	7.24%	96.43%	41.37%	41.37%
No. of shareholders	—	—	—	—	—	—	—	—	936	1,034	1,029	1,014

Promoter holding down 41.37 percentage points since Sep 2023.

7 deals · 19 Dec 2022 – 17 Jun 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
17 Jun 2026	MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED	Bulk	BSE	Buy	56,456	₹110.29	₹0.62 Cr
17 Jun 2026	NEO APEX VENTURE LLP	Bulk	BSE	Sell	55,878	₹110.29	₹0.62 Cr
12 Feb 2024	BRAHMAM SANNAMURI	Bulk	BSE	Sell	81,400	₹1.85	₹0.02 Cr
12 Feb 2024	RAMASAMY AZHAGAPPA SELVAN	Bulk	BSE	Buy	54,072	₹1.85	₹0.01 Cr
15 Jan 2024	N L RUNGTA (HUF)	Bulk	BSE	Sell	98,096	₹1.86	₹0.02 Cr
19 Dec 2022	AJITKUMAR JOGENDARPRASAD SINGH	Bulk	BSE	Sell	1,27,683	₹1.30	₹0.02 Cr
19 Dec 2022	LAXMANBHAI RAVJIBHAI GAJERA	Bulk	BSE	Buy	87,784	₹1.30	₹0.01 Cr

1–7 of 7

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mrs. JAYSHREE BABULAL JAINManaging Director
Mr. JITENDRA PRABHAKARA NENEExecutive Director
Mr. Vishal Vinod JainChief Financial Officer
Mr. Mangina Srinivas RaoNon-Executive - Independent Director
Ms. Rinku SainiNon-Executive Independent Director
Mr. Dhairyasheel Vasantrao YadavExecutive Director
Mr. Nandkumar Subhash KadamExecutive Director
Mr. Pratap Dadasaheb DeshmukhNon-Executive - Non-Independent Director
Ms. Ritu Dhanraj GaradNon-Executive - Non-Independent Director
Ms. DeepakshiCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in iSERA Lifesciences Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

30

Annual reports

18

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Dividend dividend20 Sept 2013 · ex-date₹0.5

1

Board meeting to consider results7 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

15 announcementsExport CSV

1 Oct 2026, 12:04 pmCompany Update

Announcement under Regulation 30 (LODR)-Allotment

Allotment of Equity Shares PDF

1 Oct 2026, 12:01 pmOthers

Board Meeting Outcome for Outcome Of The Board Meeting Of Isera Lifesciences Limited (Formerly Known As Covidh Technologies Limited) (The "Company") Held On October 01, 2026.

Outcome without intimation PDF

30 Sept 2026, 5:58 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

29 Sept 2026, 4:35 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

28 Sept 2026, 4:28 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

7 Sept 2026, 2:18 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

5 Sept 2026, 7:30 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

5 Sept 2026, 7:14 pmAGM/EGM

Notice Of 34Th Annual General Meeting Of Isera Lifesciences Limited (Formerly Known As Covidh Technologies Limited) For The Financial Year 2025-26

AGM PDF

Date	Category	Subject	Filing
1 Oct 2026, 12:04 pm	Company Update Allotment of Equity Shares	Announcement under Regulation 30 (LODR)-Allotment	PDF
1 Oct 2026, 12:01 pm	Others Outcome without intimation	Board Meeting Outcome for Outcome Of The Board Meeting Of Isera Lifesciences Limited (Formerly Known As Covidh Technologies Limited) (The "Company") Held On October 01, 2026.

Loading announcements…

iSERA Lifesciences Ltd

iSERA Lifesciences Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

1

1

Announcements

Not in the F&O segment

1

1

No fund holdings on record

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

iSERA Lifesciences Ltd

iSERA Lifesciences Ltd

About

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Dividends1

Board meetings1

Announcements

Not in the F&O segment

Dividends1

Board meetings1

No fund holdings on record

Announcements

Annual reports

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

1

1

1

1